MYO10-filopodia support basement membranes at pre-invasive tumor boundaries

    Emilia Peuhu, Guillaume Jacquemet, Colinda L.G.J. Scheele, Aleksi Isomursu, Marie-Catherine Laisne, Leena M. Koskinen, Ilkka Paatero, Kerstin Thol, Maria Georgiadou, Camilo Guzmán, Satu Koskinen, Asta Laiho, Laura L. Elo, Pia Boström, Pauliina Hartiala, Jacco van Rheenen, Johanna Ivaska

    Developmental Cell (2022)

    Published on December 3, 2025

    DOI: https://doi.org/10.1016/j.devcel.2022.09.016

    Core: Genome Editing Core
    ← Back to Publications
    User Publication
    Dynamic landscape of transcription initiation by yeast RNA polymerase I
    O. Parilova et al. • 2026 • Nucleic Acids Research
    Core:Protein Structure and Chemistry
    User Publication
    <i>Staphylococcus aureus</i> Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma
    M. Gluud et al. • 2026 • Allergy
    Core:Cytometry Core
    User Publication
    Fast label-free live imaging with FlowVision reveals key principles of cancer cell arrest on endothelial monolayers
    G. Follain et al. • 2026 • The EMBO Journal
    Core:Advanced Imaging Core
    User Publication
    Synthesis and Characterization of Glyco‐Decorated Silsesquioxane‐Metallosalen Complexes
    H. Haapsaari et al. • 2026 • ChemistrySelect
    Core:Protein Structure and Chemistry
    User Publication
    Functional characterization and directed evolution of Cicer arietinum glutathione transferases for enhanced hydroperoxidase activity and ligandin function
    A. Kontouri et al. • 2026 • Phytochemistry
    Core:Protein Structure and Chemistry

    More Publications

    User Publication
    December 3, 2025
    Sortilin‐related receptor is a druggable therapeutic target in breast cancer
    Hussein Al‐Akhrass, Mika Pietilä, Johanna Lilja, Ella‐Maria Vesilahti, Johanna M. Anttila, Heidi M. Haikala, Pauliina M. Munne, Juha Klefström, Emilia Peuhu, Johanna Ivaska Molecular Oncology (2021)
    In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals...
    Read abstract